Oral Vaccination Against Clostridium Difficile Infection

Clostridium Difficile Infection Clinical Trial

— CDVAX  

Official title:

Safety and Immunogenicity Study of a Clostridium Difficile Vaccine in Healthy Adult Volunteers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02991417
• Other study ID #: CDVAX
• Status: Terminated
• Phase: Phase 1
• First received: December 5, 2016
• Last updated: July 24, 2017
• Start date: January 2017
• Est. completion date: June 8, 2017

Study information

• Verified date: July 2017
• Source: Royal Holloway University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study is conducted to assess the safety and immunogenicity of a Clostridium difficile vaccine (CDVAX) in healthy adult volunteers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: June 8, 2017
• Est. primary completion date: March 14, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Written informed consent

2. Male

3. Age: 18-50 years (limits included)

4. Body mass index within 18.5 and 29.9 kg/m²

5. Ability to read and comprehend study information

6. Non-smokers or light smokers (<4 cigarettes per day)

7. In good physical and mental health as determined by the following:

1. Complete medical history

2. Complete physical and neurological examination

3. Vital signs including blood pressure, heart rate, respiratory rate, and temperature

4. Standard 12-lead ECG

5. Clinical laboratory (biochemistry, haematology and urinalysis) tests. Blood and urine samples may be drawn up to 3 weeks prior to the baseline visit of the study provided all data are available and evaluated prior to administration of study drug. Values of laboratory results outside normal reference ranges may be acceptable if the investigator considers that they do not compromise the safety of the subjects or the conduct of the study.

6. Vital signs, clinical laboratory measurements, and ECG measurements may be repeated at the discretion of the investigator

Exclusion Criteria:

1. Evidence of C. difficile infection

2. Anti-C. difficile (Toxin A) immunoreactivity, suggesting previous C. difficile exposure

3. Diarrhoea, active or inactive inflammatory bowel disease, irritable colon syndrome, chronic abdominal pain or other chronic diarrhoea

4. History of malignancy within 5 years

5. History of anaphylaxis, asthma or severe vaccine or allergic drug reaction

6. Known or suspected history of immunodeficiency, active or inactive immune-mediated or inflammatory disease

7. Receipt of antibiotic therapy, immunosuppressants, or corticosteroids within the previous 30 days

8. Vaccination within the previous 30 days (except for influenza vaccination)

9. Blood or organ donation within the previous 60 days

10. Evidence of clinically significant psychiatric, gastrointestinal, neurologic, neuromuscular, hepatic, pulmonary, cardiovascular, or renal disease (as judged by the investigator)

11. Use of prescription medication or regular use of over-the-counter medicines or herbal or dietary supplements. Acetaminophen/paracetamol may be used intermittently as needed for pain

12. History or current evidence of abuse of any drug substance, licit or illicit, including alcohol; a positive urine screen for drugs of abuse

13. Positive hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg) or positive human immunodeficiency virus (HIV)-1/2 antibodies

14. Participation in any other investigational drug or device study within 60 days prior to the first study drug administration

15. Relatives of, or staff directly reporting to the principal investigator

16. Vulnerable subjects

Related Conditions & MeSH terms

• Clostridium Difficile Infection
• Infection

Intervention

Biological:
• CDVAX

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Simon M. Cutting

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events	Measured by routine physical and laboratory evaluations, adverse event monitoring, ECG and neurological examination	First treatment up to end of treatment + 28 days (70 days after treatment start)
Secondary	Evaluation of specific mucosal and systemic immunity	Measured by specific secretory IgA, serum IgA and serum IgG	First treatment up to end of treatment + 14 days (56 days after starting study drug)